/PRNewswire/ Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to.
Diamyd Medical AB: Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes-focused life sciences company developing the first once-daily therapeutic to.
Company advancing development of lead program, iTOL-101, as a potential breakthrough in curing Type 1 Diabetes with the potential to eliminate the need for chronic life-long immunosuppressionThe up to